title: Contact dermatitis induced by glatiramer acetate.
abstract: Glatiramer acetate (Copaxone(®)) is an immunomodulatory polypeptide used in patients with relapsing-remitting multiple sclerosis. It represents a safe treatment option with mild side effects. In this study, we look at a 39-year-old woman who received glatiramer acetate as subcutaneous injections for two months and developed contact dermatitis. The drug had to be stopped, and treatment with topical prednisone was initiated. Prick/scratch testing was negative but the lymphocyte transformation test was highly positive for glatiramer acetate. This is the first report on contact dermatitis induced by glatiramer acetate injections. The treatment consisted of local topical steroids and cessation of the drug.
authors: Department of Dermatology and Allergy, Cantonal Hospital of St Gallen, Switzerland. susannehaltmeier@gmx.net
authors: S
authors: S
authors: Haltmeier
authors: M
authors: M
authors: Yildiz
authors: S
authors: S
authors: Müller
authors: M D
authors: MD
authors: Anliker
authors: L
authors: L
authors: Heinzerling
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D017449:Dermatitis, Allergic Contact / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D000068717:Glatiramer Acetate; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007279:Injections, Subcutaneous; D007428:Intradermal Tests; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects*; D011241:Prednisone / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D011241:Prednisone